NSIM
RXRX icon

North Star Investment Management’s Recursion Pharmaceuticals RXRX Stock Holding History

North Star Investment Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$562 Hold
153
– – ﹤0.01% 1648
2026
Q1 		$470 Sell
153
-1,700
-92% -$6.57K ﹤0.01% 1617
2025
Q4 		$7.58K Hold
1,853
– – ﹤0.01% 1015
2025
Q3 		$9.04K Hold
1,853
– – ﹤0.01% 931
2025
Q2 		$9.38K Hold
1,853
– – ﹤0.01% 895
2025
Q1 		$9.8K Buy
1,853
+153
+9% +$1.11K ﹤0.01% 855
2024
Q4 		$11.5K Buy
+1,700
New +$11.4K ﹤0.01% 848

Other funds holding RXRX

Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
1WA
180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return
BEI
Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
SFS
Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
KG
Kieckhefer Group Mequon, Wisconsin $246M AUM 51.29% 1-Year Est. Return
TMC
Themes Management Co Greenwich, Connecticut $151M AUM

North Star Investment Management's RXRX Position: Q2 2026 in Review

North Star Investment Management held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 153 shares worth $562. The position accounts for ﹤0.01% of the portfolio, ranked #1648.

North Star Investment Management first reported a position in RXRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $11.5K in Q4 2024. 77 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • North Star Investment Management held 153 shares of Recursion Pharmaceuticals worth $562 as of Q2 2026.
  • North Star Investment Management left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of North Star Investment Management's portfolio in Q2 2026, its #1648 holding.
  • North Star Investment Management first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • North Star Investment Management's Recursion Pharmaceuticals position peaked at $11.5K in Q4 2024.
  • 77 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on North Star Investment Management's 13F filing for Q2 2026, filed 28 Jul 2026.